| Name | DS-1040 Tosylate |
| Description | DS-1040 Tosylate is a thrombin-activated fibrinolysis inhibitor (TAFIa) inhibitor, also a fibrinolysis enhancer, inhibiting TAFIa and carboxypeptidase N, reducing fibrin clots in the lungs, useful in thromboembolic disease research. |
| In vitro | DS-1040 Tosylate inhibited human carboxypeptidase N (CPN) in vitro with an IC50 of 3.02 mM.[1] |
| In vivo | Methods: DS-1040 Tosylate (0.016, 0.031, 0.063, 0.13, 0.25, 0.50 mg/kg, intravenous injection) was administered to mice with microthrombosis model to investigate the pharmacokinetic changes in vivo.
Results: DS-1040 Tosylate increased plasma D-dimer levels in a dose-dependent manner. ED50 and EDmax were 122 and 221nM, respectively.
Methods: DS-1040 Tosylate (0.25, 0.5, 1, 2, 4, 8, 16 mg/kg; oral administration) was administered to mice with microthrombosis model to investigate the pharmacokinetic changes in vivo.
Results: DS-1040 Tosylate increased plasma D-dimer levels, with EC50 and ECmax values of 114 and 231 nmol/L, respectively.[1] |
| Storage | keep away from moisture | store at 4°C | Shipping with blue ice. |
| Solubility Information | H2O : 40 mg/mL (85.91 mM), Sonication is recommended.
DMSO : 80 mg/mL (171.82 mM), Sonication is recommended.
|
| Keywords | DS 1040 Tosylate |
| Inhibitors Related | Dabigatran Etexilate Mesylate | (S)-(+)-Ibuprofen | Edoxaban | AEBSF hydrochloride | Edoxaban Tosylate Monohydrate | Ozagrel | Menadione | Avatrombopag | Pirodomast | Argatroban | Eltrombopag Olamine | p-Hydroxycinnamic acid |
United States
